

AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently amended) A drug composition to be applied topically for promoting the regeneration of tissue, comprising microparticles from activated blood cells and/or tissues which have been purified by a process selected from the group consisting of differential centrifugation, filtration and affinity chromatography, wherein the drug composition has been subjected to a procedure selected from the group consisting of virus inactivation and virus depletion, has been prepared under sterile conditions, and is provided in a state selected from the group consisting of a freeze-dried state and a deep-frozen state.
2. (Previously presented) A drug composition according to claim 1, comprising soluble or insoluble substances promoting wound healing.
3. (Previously presented) A drug composition according to claim 1 comprising cytokines and/or growth factors.
4. (Previously presented) A drug composition according to claim 1 comprising a substance which constitutes or may form a provisional extracellular matrix.
5. (Previously presented) A drug composition according to claim 1 comprising collagen.
6. (Previously presented) A drug composition according to claim 1 comprising fibrinogen and thrombin for the formation of a fibrin scaffold.
7. (Previously presented) A drug composition according to claim 4, wherein an organic polymer is used as the provisional extracellular matrix.

8. (Previously presented) A drug composition according to claim 1 comprising inorganic compounds.
9. (Previously presented) A drug product comprising a drug composition according to any of claims 1 to 8 and a biocompatible material which is applied together with the drug composition.
10. (Previously presented) A drug product according to claim 9, wherein the biocompatible material is selected from the group consisting of titanium and an apatite.
- 11-12. (Canceled)
13. (Currently amended) The drug composition of claim 7, wherein the organic polymer is a polyacton polyactin.
- 14-16. (Canceled)